Quarterly ResultMay 7, 2026, 09:22 AM
Iovance Biotherapeutics Q1 Revenue ~$71M, +45% YoY; Strong Guidance
AI Summary
Iovance Biotherapeutics reported strong first quarter 2026 financial results, with total product revenue reaching approximately $71 million, a 45% increase year-over-year. The company provided optimistic guidance, projecting Q2 2026 total product revenue between $86 million and $88 million, and full-year 2026 revenue of $350 million to $370 million. Additionally, Iovance highlighted positive initial data from its IOV-END-201 trial in metastatic serous endometrial cancer, showing a 40% confirmed objective response rate, and announced progress across its pipeline and global commercial expansion for Amtagvi.
Key Highlights
- Iovance Biotherapeutics Q1 2026 total product revenue was ~$71 million, up ~45% YoY.
- U.S. Amtagvi revenue reached ~$60 million in Q1 2026.
- Q1 2026 net loss was $(79.0) million, or $(0.19) per share.
- Company forecasts Q2 2026 total product revenue of $86 million to $88 million.
- Full-year 2026 total product revenue guidance is $350 million to $370 million.
- IOV-END-201 trial showed 40% objective response rate in metastatic serous endometrial cancer.
- Cash, cash equivalents, and investments totaled ~$319 million as of March 31, 2026.
- Research and Development expenses decreased by 12% compared to Q4 2025.
Price Impact
More from IOVA